Hashim U. Ahmed
Led PROMIS, the trial that showed MRI can safely spare a quarter of men from prostate biopsy.
Overview
Hashim Ahmed (Imperial College London) was chief investigator of PROMIS, which showed multiparametric MRI has far higher sensitivity for clinically significant prostate cancer than TRUS biopsy and could allow 27% of men to avoid biopsy altogether. He leads focal therapy trials of HIFU and cryotherapy and the PART and CHRONOS studies comparing focal and radical treatment.
| Title | Journal | Year |
|---|---|---|
| Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS) | Lancet | 2017 |
| Focal therapy for localised prostate cancer: a phase I/II trial | Lancet Oncology | 2012 |
Pages like this
not linked directly; found by shared links- PersonMark Emberton
Shares PRECISION, Focused ultrasound & histotripsy, MRI, Prostate cancer and the tags prostate, imaging, focal-therapy.
- CompanySonALAsense
Shares Focused ultrasound & histotripsy, MRI.
- TechnologyMultiparametric prostate MRI (PI-RADS)
Shares PRECISION, MRI, Prostate cancer.
- PersonDeclan G. Murphy
Shares Prostate cancer and the tags prostate, imaging.
- TechnologyPhotothermal (plasmonic) nanoparticle ablation
- CompanyAdialante
Shares MRI, Prostate cancer.
- IdeaProstate active surveillance without scheduled biopsies: MRI and blood tests decide
Shares MRI, Prostate cancer.
- PersonMatthew R. Smith
Shares Prostate cancer and the tag prostate.